The Indian majors in
the pharma sector has substantially increased their R&D budgets to
develop new compositions/molecules to withstand the new threats under the
New IPR Regime as per study by Administrative Staff College of India, Hyderabad.
R&D
Expenditure of top Indian companies.
|
Company
|
R&D exp. in crores
|
Amount % of sales.
|
| Ranbaxy |
55 |
2.93 |
| Wockhart |
42 |
4.78 |
| Nicholas |
10 |
1.89 |
| Cipla |
24 |
3.84 |
| Lupin |
10 |
1.70 |
| Dr Reddy |
13 |
2.70 |
| Aurobindo |
14 |
1.95 |
AstraZeneca is going
to spend $10 million for research in tuberculosis other such infectious
diseases in its research centre at Bangalore, according to its Chief Scientist
Dr Barry Furr.This would form part of her global research infrastructure
operated at an annual expense of $2.5 billion.
|